

Data Article

Survival Times of Breast Cancer Patients in Nigeria

Abstract

This paper presents comprehensive research into the survival times of breast cancer patients in Nigeria. Breast cancer is a significant global public health concern, and its impact is particularly profound in Nigeria due to unique socioeconomic, cultural, and healthcare access factors. This study synthesizes data from seventeen studies to provide a more robust estimation of survival times, enhance generalizability, and identify potential sources of heterogeneity among different cohorts. A comprehensive literature search of articles published about the survival rate of breast cancer in Nigeria was conducted using a snowballing approach in major electronic databases. Seventeen (17) publications were found to meet the inclusion criteria and were selected for the meta-analyses. R was used to perform all the analyses. The results showed that the survival rates for breast cancer in Nigeria were 66.98% at one year, 96.40% at three years, 99.61% at five years, and 99.99% at ten years. The study's findings underscore both the challenges and progress in breast cancer mortality in the Nigerian context. Cancer makes people anxious, and anxiety affects value, so to improve survival rates and overall patient care, the Nigerian government should include mental health professionals in managing cancers. The findings of this study contribute to the global discourse on cancer management while also providing a tailored framework for improving outcomes within the unique Nigerian perspective.

INTRODUCTION

Breast cancer development involves multiple cell types undergoing successive transformations [1]. Breast cancer, a form of malignancy originating in breast tissue, affects millions of women annually, establishing it as the predominant cancer among women on a global scale [2]. The tumour originates as ductal growth and evolves into benign or malignant cells due to exposure to carcinogenic agents. The tumour microenvironment, encompassing factors such as stromal origin and macrophage-mediated immune response, influences disease progression. The formidable capacity of metastatic breast cancer to disseminate to distant tissues and organs, including the liver, lungs, and brain, complicates therapeutic interventions. Early breast cancer detection substantially elevates patient survival rates and reduces overall mortality, particularly in developed nations [3].

Established risk factors exist for breast cancer, notwithstanding the intricate and partial comprehension of breast cancer's biology [4]. Advancing age and female gender are foremost among these risk factors. Genetic mutations, especially BRCA1 and BRCA2, account for roughly 10% of breast cancer instances. Moreover, acknowledged risk elements encompass a record of ductal carcinoma in situ, elevated body mass index, nulliparity or premature menarche (before age 13), familial history of breast or ovarian cancer, delayed menopause, and postmenopausal hormone therapy usage.

As of 2020, the globally reported breast cancer cases reached 2.26 million, rendering it the most widespread cancer [5]. Furthermore, it is the principal cancer affecting women in developing and developed nations, constituting a substantial public health challenge [5]. Ethnicity and race contribute to variations in the incidence rates, and despite its worldwide occurrence, it holds

greater prominence in developed nations [3]. In 2020, breast cancer accounted for 685,000 fatalities, ranking as the fifth leading cause of cancer-related deaths worldwide [5]. Ferlay et al. [6] stated that an estimated 6.3 million women have previously been diagnosed and are currently living with breast cancer. In 2012, nearly 1.68 million new cases were reported, with a notable surge to about 2.1 million new cases in 2018 [7]. Unfortunately, the mortality rates also followed a similar upward trend, registering a 14% rise [8].

Globally, breast cancer impacts many women annually by inciting uncontrolled cell proliferation, resulting in tumour growth [2]. This affliction accounted for over 570,000 deaths in 2015 alone, emerging as the foremost cause of female mortality worldwide [1]. In the United States, an estimated 252,710 new female cancer cases in 2017 were attributed to breast cancer, encompassing 30% of all new cancer cases [9]. A parallel scenario is observed in the UK, with an anticipated 286,600 new breast cancer cases projected for 2019 [9].

Unlike developed regions where breast cancer ranks as the second most common cause of cancer-related mortality after lung cancer, in developing parts of the world such as Nigeria, breast cancer takes the lead as the primary cause of cancer-related deaths in women [7, 6]. Historically limited, the incidence of breast cancer cases in Nigeria is progressively surging due to urbanisation and lifestyle adjustments. Breast cancer constitutes approximately 22.7% of total cancer diagnoses (Figure 1) and roughly 25.5% of mortalities, positioning it as the predominant contributor to cancer-related deaths [10].




Figure 1: Number of new cases in 2020, both sexes, all age




Figure 2: Age-standardized (World) incidence rates per sex, top 10 cancers

Breast cancer represents a critical public health concern in Nigeria, and it is essential to grasp the survival times of breast cancer patients to enhance treatment outcomes and healthcare planning.

By 2022, Nigeria's population exceeded 218 million, establishing it as the most populous country in Africa. Nigeria is characterised by over 250 ethnic groups, the nation embodies remarkable diversity [11]. In a study involving young women with breast cancer treated at the University College Hospital in Ibadan, Nigeria, encompassing those aged forty (40) years or younger, a total of 763 cases were evaluated, of which 221 (28.96%) pertained to individuals under the age of 40. Five individuals (2%) exhibited stage I disease, while 29 (13%) presented stage II disease. Notably, stages III and IV were detected in 102 (46%) and 85 (39%) of patients, respectively [12].

Based on data from the Ibadan Cancer Registry, breast cancer contributes 40.8% of all female cancers [13]. Empirical studies indicate that age-standardised breast cancer incidence rates in Nigeria surged over two-fold from 1960 to 2000, increasing nearly 25% per decade [14]. Breast cancer constitutes the most prevalent malignancy, comprising about 23% of the 5,000 cases examined at the University College Hospital's Radiotherapy Centre in Ibadan, Nigeria [15].

Country-specific 5-year overall survival rates [16], exhibit variation. For instance, Canada displays an 88% survival rate, the United States a 90% rate, and South Africa reports rates of 80% for whites and 64% for blacks [17]. Conversely, a study conducted in Nigeria by Popoola, Ogunleye, and Ibrahim [18] revealed that a group of breast cancer patients examined in Lagos attained an overall 5-year survival rate of 25.6%. According to the study by Atoyebi [2], there is an overall one-year survival rate of 77.4%.

As indicated by Alabi et al. [19], the cumulative overall survival probability stands at 0.175 (17.5%), with an estimated global mean survival period of 28.751 weeks. The typical interval between admission and death is approximately 23 weeks. The p-value (0.00032) from the

comparison of tumour stage survival rates, being less than 0.05, signifies substantial evidence of variance in survival rates associated with tumour stages. Assessment of the survival function map across diverse tumour stages suggests a diminished chance of survival for stage III patients. The prognosis further suggests that patients with stage I tumours exhibit a heightened likelihood of survival.

Regarding the 2- and 5-year survival rates, Ali-Gombe et al. [20] reported rates of 56.4% and 37.6%, respectively. Stage I indicated the highest 2- and 5-year survival rates at 80.0% and 66.7%, followed by stage II (67.7% and 57.6%), stage III (51.4% and 27.9%), and stage IV (37.9% and 13.8%). The median survival time (95% CI = 35.0-44.0) was established at 41 months. Disease-free survival rates at 2 and 5 years were documented as 66.6% and 60.3%, respectively, with recurrence occurring within a median of 8.0 months. Statistically significant associations with survival were noted for factors such as the presence of distant metastases, clinical axillary lymph node metastasis, supraclavicular node metastasis, mode of surgery, height, tumour unilaterality, clinical tumour size, and stage at presentation, among others.

RESEARCH AIM

This research aims to ascertain breast cancer patients' historical and contemporary survival times in Nigeria while identifying potential disparities across various studies. Synthesis of data from multiple studies allows this research to provide a more robust estimation of survival times, enhance generalizability, and identify potential sources of heterogeneity among different cohorts. This study on the survival times of breast cancer in Nigeria carries immense significance for various stakeholders, including healthcare practitioners, policymakers, and breast cancer

patients. Ultimately, this study is expected to improve breast cancer management and patient care in Nigeria. Understanding the survival times of breast cancer patients can profoundly impact healthcare policy and decision-making in the country.

METHODS

Research Design

This study aimed to achieve its research objective by utilising quantitative Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA-P). During the execution of this review, adherence to the PRISMA-P guidelines was ensured. The article search initiative commenced on April 3, 2023, concluding on June 14, 2023. PRISMA-P involves the analysis of secondary data, specifically quantitative data obtained from previous research findings. As a retrospective observational research approach, the meta-analysis compiles and summarises data without experimental manipulation [2]. Meta-analysis is a statistical technique used to combine and analyse the results of multiple independent studies on the same research question or topic. Meta-analysis, involving processed data derived from computed measurements, is a valuable tool for summarising research outcomes, supporting policy formulation, and drawing statistical inferences [21]. Following the PRISMA-P guidelines ensures transparency in the systematic review and meta-analysis process. Clearly documenting the research aim, search strategies, inclusion/exclusion criteria, and planned statistical methods helps provide a clear roadmap for other researchers to understand and replicate your study. Applying PRISMA-P enhances the understanding and utilisation of evidence for decision-makers [22].

Data extraction and quality assessment

For streamlined review, pertinent data from selected research was extracted and organised in a tabular format. The assessment of controlled intervention, observational, and cohort studies was aided by National Institutes of Health quality assessment tools [23]. The evaluation criteria encompassed the rational and clear articulation of objectives, suitability of methodology for objectives, and accurate depiction of study populations. Ratings of “good,” “middling,” or “bad” were assigned based on affirmative responses to quality assessment tool criteria, in line with the National Heart, Lung, and Blood Institute’s delineated thresholds [23].

Furthermore, the evaluation of WHO publications retrieved via grey literature searches employed the open-source CRAAP guidance and template developed by the Sheridan Libraries at Johns Hopkins University [24]. This acronym-based framework assessed the information’s authority, relevance, currency, accuracy, and intent, thus ensuring its quality [24]. Since the inclusion/exclusion criteria already accounted for relevance, the parameter “Relevance” was deemed redundant and excluded.

Literature searches

Comprehensive database searches were executed in MEDLINE, Pubmed Central, EMBASE, Google Scholar, Web of Science, and Researchgate to locate published peer-reviewed journal articles and research on breast cancer in Nigeria. Exploring all these databases entailed a combination of ‘Medical Subject Headings’ phrases and free text for effective search queries. The search encompassed distinct concepts, and their synonyms, synergised by Boolean operators, yielding the resultant search string: “Breast Cancer AND Survival rates AND Survival

times AND (Nigeria)”. The search for grey literature was facilitated by consulting the WHO, Google Scholar databases, and Africa Wide. The relevant URL was included in Google searches with additional keywords to refine the outcomes, such as “Breast cancer survival times in Nigeria. Aricawide.com”.

Data extraction and Article screening and

The specified Population, Intervention, Control, Outcome, Time, and Study Design (PICOTS) criteria, as detailed in Table 1, formed the basis for the comprehensive review of full-text articles. The authors performed the article title and abstract screening, thoroughly reviewing the articles. Using the PICOTS framework for this study is considered appropriate because it provides a structured approach to formulating a research question that considers all relevant aspects of the analysis. This ensures that the meta-analysis is focused, well-defined, and capable of generating meaningful insights into survival outcomes for breast cancer patients in Nigeria.

Table 1: Criteria for Article Screening Based on PICOTS

Population/Participants	<p>Accessible articles detailing the survival rates of breast cancer in Nigeria were identified via electronic searches or obtained through corresponding author requests. Articles had to furnish data concerning the sample size and survival rates to be eligible. Articles with a singular focus on other types of cancer and article about breast cancer without a focus on survival rates were excluded from consideration.</p> <p>Moreover, international research providing insights into Nigerian</p>
-------------------------	--

	<p>breast cancer data was incorporated.</p> <p>Only articles authored in English or translated into English were considered eligible. Only articles published from 2010 and above were included. Only research that uses primary data was included.</p>
Intervention	Treatment modalities include surgery, chemotherapy, radiation therapy, targeted therapy, and hormonal therapy.
Control	Patients that received standard care or placebo, or comparisons between different treatment modalities.
Outcomes	1. Overall survival rates, 2. Progression-free survival, 3. One-year, Five-year and ten-year survival rates, 4. Survival disparities based on different treatment approaches
Time	<p>The study encompassed articles published from January 2010 to August 2023.</p> <p>Survival data was collected over a span of 5 to 10 years, with varying follow-up periods depending on available studies.</p>
Study design	The research design was not a strict exclusion criterion, provided that relevant data on survival rate and/or outcome variables could be extracted. The inclusion criteria encompassed original research featuring a sample size of 10 patients, from which data related to at least one of the designated outcomes could be extracted, treated, or

	monitored.
--	------------

Sensitivity analysis

Sensitivity analysis is a critical component of meta-analysis. Sensitivity analysis involves assessing the robustness and reliability of the results of a meta-analysis by systematically varying different aspects of the analysis to determine their impact on the overall findings. The stability of the study's outcomes was further evaluated through a sensitivity analysis. The statistical significance of the results remained unaltered even upon the exclusion of particular publications from the analysis, affirming the precision and coherence of our findings. Publication bias, subgroup analyses, and heterogeneity were also examined to to evaluate the influence of various factors on the summary effect size or conclusion drawn from the combined studies.

Newcastle Ottawa Scale assessment of the quality of evidence

For quality assessment, we adapted the Newcastle-Ottawa quality assessment tool. The Newcastle-Ottawa Scale evaluates studies based on three key domains: selection of study groups, comparability of groups, and ascertainment of the exposure or outcome of interest. Each domain is assessed through a series of criteria in this study, and the study is assigned stars (points) accordingly.

Statistical analysis

The outcomes encompassed summaries of variable estimates aligned with our PICOTS criteria. Meta-analysis was conducted through the R software. A random-effect model employing the double arcsine transformation was employed to generate summary estimates, thus averting the undue influence of studies with values approximating 100% or 0%. The heterogeneity test was conducted to assess whether the observed variation in effect sizes is statistically significant. Addressing the statistical interdependence among different effect sizes within a single sample, specifically effect sizes nested within samples, can be achieved using the random-effects robust standard error estimator [25]. A low p-value (e.g., less than 0.05) will suggest significant heterogeneity. Subgroup analyses were performed based on different treatment groups within the variable.

RESULTS AND DISCUSSION

Study Selection




Figure 3: Study Selection

The initial search yielded eight hundred and eight (808) publications related to the research objective. Subsequently, four hundred and five (435) studies were assessed for eligibility based

on predetermined criteria. After carefully evaluating the full-text articles, seventeen (17) publications met the inclusion criteria and were selected for the meta-analysis. Consequently, four hundred and eighteen (418) studies were excluded for several reasons some publications did not report survival rates data, some did not include the sample size, some sample sizes were less than ten (10), some studies added another type of cancer to breast cancer in their study, or failure to meet the specified criteria. During the selection process, duplicates were removed, and the remaining articles' titles, abstracts, and full texts were thoroughly scrutinised to ensure their relevance and suitability for the study. Figure 3 provides a visual representation of the selection process.

The characteristics of the 17 included studies are summarised in Table 2, showcasing their diverse origins from six (6) regions of Nigeria. These 17 studies encompassed data from five thousand six hundred and sixty-five (5665) breast cancer patients.

Study characteristics




Chart 1: Forest plots

Chart 1 presents the utilisation of forest plots, a graphical representation to exhibit the 95% confidence interval survival rate estimates of each study that has been chosen, alongside the pooled survival rate estimates.

Table 2: Characteristics of Studies

Author	Year	Study Design	State	Sub-regions
Nabegu et al. [26]	2023	Retrospective study	Kano	North West
Akanno et al. [27]	2023	Cox and Parametric Survival Models	Imo	South East
Agodirin et al. [28]	2023	Prospective study	Kwara	North Central
Olaogun et al. [29]	2023	Prospective study	Ekiti	South West
Alabi et al. [30]	2022	Kaplan-Meier (K-M)	Oyo	South West
Gregory et al. [31]	2021	Prospective study	Osun	South West
Ali-Gombe et al., [20]	2021	Retrospective cross-sectional study	Oyo	South West
Olalekan et al. [32]	2021	Prospective study	Osun	South West
Julius et al. [33]	2020	Descriptive retrospective study	Ekiti	South West
Usman and Awosan [34]	2020	Retrospective study	Sokoto	North West
Awodutire et al. [35]	2020	Retrospective study	Osun	South West
Popoola et al., [36]	2019	Cox proportional hazard regression analysis	Oyo	South West
Ayandipo et al. [37]	2019	Prospective cohort study	Oyo	South West
Ntekim, et al. [38]	2019	Observational retrospective study	Gombe	North East
Olakanmi et al. [39]	2015	Retrospective study	Lagos	South West
Makanjuola et al.[40]	2014	Cox proportional hazard	Lagos	South West
Kene, et al. [41]	2010	Retrospective	Kaduna	North West




Figure 4: Years of Publications

Table 2 and Figure 4 demonstrate the trend of publications over the years understudied. The data encompasses studies published from 2010 to 2023. The number of studies seems to have increased over the years, with more studies published in recent years (2020-2023) compared to earlier years.

Random effects analysis and exploration of heterogeneity

The analysis was based on data from 17 studies. The tau-squared (τ^2) estimator used for estimating the amount of total heterogeneity is REML (Restricted Maximum Likelihood). The estimated value of τ^2 , representing the amount of total heterogeneity across the studies, is 0.7144 with a standard error of 0.2527. The square root of the estimated τ^2 value is approximately 0.8452. The I-squared (I^2) statistic, the proportion of total variability attributed to heterogeneity, is 100.00%. This suggests substantial variability between the studies. The H-squared (H^2) statistic is 135537.52. The value of Q statistic, which tests for heterogeneity, is 3267908.0579

with degrees of freedom (df) equal to 16 with a p-value of less than 0.0001, indicating strong evidence of heterogeneity among the studies.

The estimated pooled effect size (estimate) is 1.1082, indicating an overall increase in the hazard of breast cancer events across the studies, with the estimate of standard error being 0.2051. The z-value (zval) is 5.4042, suggesting that the estimate is statistically significant with the p-value (pval) associated is less than 0.0001, further supporting the statistical significance of the pooled effect. The estimate's confidence interval (CI) is reported with lower and upper bounds (ci.lb and ci.ub) as 0.7063 and 1.5101, respectively. These results indicate significant heterogeneity among the studies, with a substantial proportion of total variability attributed to differences between the studies. The pooled effect size suggests an overall increase in the hazard of breast cancer events. The statistical significance of the estimate and the narrow confidence interval further reinforces the findings.

Analysis of Pooled Survival Times

The pooled 1-year, 3-year, 5-year, and 10-year survival rates of patients with breast cancer in the regions were as follows: 1-year survival rate: 0.6698428; this means that around 66.98% of patients are expected to survive at least one year after diagnosis. 3-year survival rate: 0.9640116; this indicates that around 96.40% of patients are expected to survive at least three years after diagnosis. The 5-year survival rate of 0.9960771 suggests that most patients, around 99.61%, are projected to survive at least five years after diagnosis. The estimated ten-year survival rate is even higher, at approximately 0.9999846. This signifies that a very large proportion of patients, around 99.99%, are expected to survive at least ten years after their breast cancer diagnosis.

Subgroup Analysis

The outcomes of the mixed-effects meta-analysis was conducted to determine the survival rates in different Sub-Regions for breast cancer patients in Nigeria, the estimated value of τ^2 , representing the amount of residual heterogeneity unaccounted for by moderators, is 0.5921 with a standard error of 0.2420. The square root of the estimated τ^2 value is approximately 0.7695. The I-squared (I^2) statistic indicates that 100.00% of the residual heterogeneity remains unaccounted for. The H-squared (H^2) statistic is 81018.27, reflecting unaccounted variability in relation to sampling variability. The R-squared (R^2) statistic is 17.12%, indicating the proportion of heterogeneity accounted for by moderators.

The QE statistic test is 1023417.0427 with degrees of freedom (df) equal to 12. The p-value associated with the QE statistic is less than 0.0001, signifying strong evidence of residual heterogeneity. The QM statistic tests for the impact of moderators, focusing on coefficients 2 to 5 (related to Sub-Regions). The QM statistic is 7.3022 with $df = 4$. The p-value associated with the QM statistic is 0.1208, greater than 0.05, suggesting no significant impact of the moderators on the model. The interpretation of the results suggests that the survival rates across the different subregions (North East, North West, South East, and South West) are not statistically significantly different from each other. The p-values associated with the estimated effects of subregions are all greater than the conventional significance level (e.g., 0.05), indicating no strong evidence to suggest that the survival rates vary significantly across these subregions.

However, the high residual heterogeneity ($I^2 = 100.00\%$) suggests substantial variability among the study outcomes that the model does not explain.

Publication Bias

The analysis of precision asymmetry funnel plots and Egger's test indicated that the included studies did not suffer from publication bias. The results of Egger's test showed that publication bias was not statistically significant, as the p-value of 0.9551 indicates the absence of publication bias in this analysis. The t-value of 0.06 also supports this finding. This symmetry in the funnel plots suggested that the conclusions drawn from the studies were not influenced by publication bias. Therefore, the findings from this analysis are less likely to be distorted by biased reporting of studies, providing more confidence in the reliability of the results.




Figure 5: Flow Chart for Publication Bias

Table 3: Study Quality Assessment Using Newcastle-Ottawa Scale (NOS)

Study ID	Selection	Comparability	Exposure/Outcome	Total Stars
1	★★★★☆	★★★★	★★★★★	12/15
2	★★★★☆	★★★★☆	★★★★★	11/15
3	★★★★☆	★★★★	★★★★★	12/15
4	★★★★☆	★★★★	★★★★★	12/15
5	★★★★☆	★★★★☆	★★★★☆	10/15
6	★★★★☆	★★★★	★★★★★	12/15
7	★★★★☆	★★★★☆	★★★☆☆	10/15
8	★★★★☆	★★★★	★★★☆☆	11/15
9	★★★☆☆	★★★★☆	★★★★★	10/15
10	★★★★☆	★★★★☆	★★★★★	11/15
11	★★★★☆	★★★★☆	★★★★★	11/15

Study ID	Selection	Comparability	Exposure/Outcome	Total Stars
12	★★★★☆	★★★☆☆	★★★☆☆	10/15
13	★★★★☆	★★★★★	★★★☆☆	11/15
14	★★★★☆	★★★★★	★★★★★	12/15
15	★★★★☆	★★★☆☆	★★★★★	11/15
16	★★★★☆	★★★☆☆	★★★★★	11/15
17	★★★★☆	★★★★★	★★★★★	12/15

As shown in Table 3, the maximum possible score is 15 stars, with more stars indicating higher study quality. The selection domain includes representativeness of the exposed cohort, non-exposed cohort selection, and exposure ascertainment. The comparability domain assesses the comparability of cohorts based on the design or analysis. The exposure/Outcome domain evaluates the assessment of outcome, follow-up period, and adequacy of follow-up. These results show that all the studies have higher NOS scores, implying that they are more methodologically rigorous and likely to produce more reliable and valid results.

DISCUSSION

This study aims to estimate breast cancer survival rates in Nigeria through a meta-analysis of available data. The results highlight both the challenges and progress in breast cancer survival rates in the Nigerian context. The meta-analysis yielded the following survival rates for breast cancer in Nigeria: 66.98% at one year, 96.40% at three years, 99.61% at five years, and 99.99% at ten years.

Nigeria's 1-year survival rate (66.98%) is notably lower than England's (96%) and Australia's (98.1%) rates in 2009 [42]. This discrepancy can be attributed to several factors, primarily the underdeveloped health system, resulting in delayed diagnoses and inadequate treatment. Deficiencies in management capacities, screening measures, diagnostic procedures, and prevention efforts are also contributing factors [43]. Socioeconomic disparities and limited access to diagnostic resources are intertwined with a nation's economic status, impacting survival rates [44].

Breast cancer survival rates in Africa are generally lower compared to developed nations [2]. In Nigeria, factors like limited breast cancer knowledge and obstacles to healthcare accessibility contribute to late diagnosis and poor survival rates [2, 45, 46, 47]. Deficiencies in management capacities, diagnostic capabilities, screening, prevention, and timely diagnoses amplify this situation. Access to diagnostics is a global challenge, affecting nearly half of the world's population [43].

However, Nigeria's breast cancer survival rates at one year are comparable to those of China and India. Chinese studies reported 1-year and 3-year survival rates of 76.0–83.1% and 51.5–74.1%, respectively [48], while Indian studies found rates of 76% and 51.5% [51]. Relative 5-year survival rates ranged from 52% in India to 82% in China [49], suggesting similarities between Nigeria's 1-year survival rates and those in developed and developing countries.

Breast cancer survival rates in Nigeria are higher at five years and 99.99% at ten years. This higher survival rate might be because of a lack of data; it could be that breast cancer in Nigeria stops attending clinics after a few years of managing breast cancer. The absence of efficient population-based cancer registries in Nigeria impedes comprehensive surveillance and control

programs. Factors such as a lack of faith in healthcare quality and misconceptions about breast cancer contribute to patients avoiding clinics, resulting in delayed treatment [51, 52].

While positive, Nigeria's high survival rates still fall short of developed countries like the United States. American Cancer Society data from 2015–2016 reported relative survival rates of 89% at five years and 83% at ten years. Similarly, European studies found rates ranging from 69% to 84% [53]. Notably, these rates have consistently improved over time in various nations, including Canada and England [54, 42].

CONCLUSION

Breast cancer is a significant health concern globally, and Nigeria is no exception to this challenge. Breast cancer poses a considerable burden on both public health and healthcare systems in the country. The study's findings underscore the progress in breast cancer survival rates in Nigeria, with rates increasing over 1, 3, 5, and 10 years. This study shows that there are still challenges due to gaps in the healthcare system and awareness, hindering timely diagnoses and treatment. This study serves as a significant stepping stone towards a better understanding of breast cancer survival dynamics in Nigeria. The insights gained from this research contribute to the global discourse on cancer management and provide a tailored framework for improving outcomes within the unique Nigerian context. As progress is made in implementing the recommendations, it is anticipated that breast cancer patients in Nigeria will experience improved survival times and enhanced quality of life, ultimately positively impacting the nation's health landscape.

However, it is important to acknowledge the limitations of this study. The analysis, while comprehensive, is based on available data and may not encompass all possible influencing factors. Furthermore, the dynamic nature of healthcare systems and societal changes necessitates continuously reevaluating strategies and interventions.

RECOMMENDATIONS

Based on the findings and insights derived from the comprehensive study on breast cancer survival times in Nigeria, the following recommendations are formulated to enhance breast cancer management, healthcare planning, and policy formulation within the Nigerian context:

To improve survival rates and overall patient care, the Nigerian government should include mental health professionals in managing cancers, such as a therapist or counsellor who specialises in anxiety and can provide cancer patients with tailored strategies and support. Cancer makes people anxious, and anxiety affects value. Cancer diagnosis and treatment can significantly impact a person's psychological well-being, often leading to heightened stress levels.

Policymakers and healthcare authorities should prioritise establishing and maintaining comprehensive cancer registries to track trends, monitor progress, and inform evidence-based decisions. Data-driven insights from these registries can guide resource allocation and targeted interventions.

Collaborative efforts among medical oncologists, surgeons, radiologists, and other healthcare professionals are essential for providing comprehensive and holistic care to breast cancer

patients. Strengthening interdisciplinary teamwork and promoting the adoption of evidence-based treatment guidelines can lead to more effective and personalised treatment plans, consequently improving survival rates.

Public awareness and eradication of stigma should be prioritised. A comprehensive strategy to raise public awareness about breast cancer, dispel myths, and reduce stigma is essential. Educating communities about the disease, encouraging open conversations, and challenging cultural taboos surrounding breast health can contribute to earlier diagnoses and improved treatment outcomes.

UNDER PEER REVIEW

REFERENCES

1. Sun, Y.S., Zhao, Z., Yang, Z.N., Xu, F., Lu, H.J., Zhu, Z.Y., Shi, W., Jiang, J., Yao, P.P. and Zhu, H.P., 2017. Risk factors and preventions of breast cancer. *International journal of biological sciences*, 13(11), p.1387.
2. Atoyebi, S.B., 2023. Survival Times of Lung, Breast, Cervical, and Prostate Cancer Patients in Africa. *Journal of Cancer and Tumor International*, 13(1), pp. 9-28
3. DeSantis, C.E., Fedewa, S.A., Goding Sauer, A., Kramer, J.L., Smith, R.A. and Jemal, A., 2016. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. *CA: a cancer journal for clinicians*, 66(1), pp.31-42.
4. Watkins, E.J., 2019. Overview of breast cancer. *Journal of the American Academy of PAs*, 32(10), pp.13-17.
5. Who.int. 2021. Cancer. Retrieved 9 June 2023, from <https://www.who.int/news-room/fact-sheets/detail/cancer>.
6. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. and Bray, F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5), pp. 359-386.
7. WHO. 2018. Latest world cancer statistics, global cancer burden rises to 2.1 million new cases in 2018: Marked increase in breast cancer must be addressed. [http://globocan.iarc.fr]. GLOBOCAN 2018, International Cancer Research Institute of the World Health Organization. Lyon.
8. WHO. 2013b. Latest world cancer statistics, global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancer must be addressed.

[<http://globocan.iarc.fr>]. GLOBOCAN 2012, International cancer research institute of the World Health Organization. Lyon.

9. Siegel, R.L., Miller, K.D. and Jemal, A., 2018. Cancer statistics, 2018. *CA: a cancer journal for clinicians*, 68(1), pp.7-30.
10. Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I. and Bray, F., 2020. Global cancer observatory: cancer today. International Agency for Research on Cancer. *Lyon, France*.
11. Atoyebi S.B., Olayiwola M.F., Oladapo J.O., and Oladapo D.I 2023. Forecasting Currency in Circulation in Nigeria Using Holt-Winters Exponential Smoothing Method. *South Asian Journal of Social Studies and Economics*. 20(1), pp.25-41
12. Ntekim, A., Nufu, F.T. and Campbell, O.B., 2009. Breast cancer in young women in Ibadan, Nigeria. *African health sciences*, 9(4).
13. Jedy-Agba, E., Curado, M.P., Ogunbiyi, O., Oga, E., Fabowale, T., Igbinoba, F., Osubor, G., Otu, T., Kumai, H., Koechlin, A. and Osinubi, P., 2012. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer epidemiology*, 36(5), pp.e271-e278.
14. Parkin, D.M., Ferlay, J., Hamdi-Cherif, M., Sitas, F., Thomas, J.O., Wabinga, H. and Whelan, S.L., 2003. Cancer in Africa. *Epidemiology and prevention*, 4, pp.268-276.
15. Campbell, O., Agwimah, R., Oduola, B. and Alawale, E., 1998. Radiotherapy management of breast cancer in 400 Nigerians. *Niger Med J*, 16, p.48.
16. Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J. and Ogunbiyi, O.J., 2018. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual

records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*, 391(10125), pp.1023-1075.

17. Vorobiof, D.A., Sitas, F. and Vorobiof, G., 2001. Breast cancer incidence in South Africa. *Journal of clinical oncology*, 19(18; SUPP), pp.125s-125s.
18. Popoola, A.O., Ogunleye, O.O., Ibrahim, N.A., Omodele, F.O. and Igwilo, A.I., 2012. Five year survival of patients with breast cancer at the Lagos State University Teaching Hospital, Nigeria. *J Med Med Sci Res*, 1, pp.24-31.
19. Alabi, O.O., Saula, A.Y., Gayawan, E., Alabi, V.S., Bello, H.A., Akinbo, R.Y. and Lasisi, T.A., 2022. Survival Rate Analysis on Breast Cancer Cases at Univesity College Hospital, Ibadan, Nigeria. *Open Journal of Statistics*, 12, pp.238-260.
20. Ali-Gombe, M., Mustapha, M.I., Folasire, A., Ntekim, A. and Campbell, O.B., 2021. Pattern of survival of breast cancer patients in a tertiary hospital in South West Nigeria. *ecancermedicalscience*, 15.
21. Atoyebi, O.M. and Atoyebi, S.B., 2022. Do technology-based approaches reduce mathematics anxiety? A Systematic literature. *International Journal of Research and Innovation in Social Science (IJRISS)*, 6(10), pp.502-509.
22. Atoyebi, S.B. and Atoyebi, O.M., 2022. The link between mathematics teaching strategies and students' anxiety. *Asian Journal of Education and Social Studies*, 33(4), pp.48-57.
23. National Institutes of Health. Study quality assessment tools. Natl Institutes Heal. 2018;1-35
24. Johns Hopkins Sheridan Libraries. Guides: evaluating information. 2018. <http://guides.library.jhu.edu/evaluate> (accessed 24 April 2023)

25. Atoyebi, O.M. and Atoyebi, S.B., 2022. A Meta-analytic Review of the Relationship between Mathematics Anxiety and the Mathematical Thinking of Africa Students. *Archives of Current Research International*, 22(7), pp.15-28.
26. Nabegu, A.A., Muhammad, M.U. and Abdullahi, N., 2023. Survival Analysis of Breast Cancer Patients In Kano State. *FUDMA Journal of Sciences (FJS)*, 7(2), pp.199-205.
27. Akanno, F.C., Obasi, C.C., Chukwuocha, U.M., Dozie, U.W., Ori, C.L.U., Sule, G.I.O., Ijeoma-Ogu, A. and Innocent, D.C., 2023. Survival Times of Breast Cancer Patients in Nigeria: Application of Cox and Parametric Survival Models. *African Journal of Biology and Medical Research*, 6(2), pp. 84-97.
28. Olayide, A., Isiaka, A., Ganiyu, R., Samuel, O., Halimat, A., Olalekan, O., Julius, O. and Anya, R., 2023. Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis. *Asian Pacific Journal of Cancer Care*, 8(3), pp.591-598.
29. Olaogun, J., Agodirin, O., Etonyeaku, A. and Idowu, D. 2023. Metastatic Breast Cancer in a Tertiary Hospital in South-Western Nigeria. *Turkish Journal of Oncology*, 38(2), pp. 162-169.
30. Alabi, O.O., Saula, A.Y., Gayawan, E., Alabi, V.S., Bello, H.A., Akinbo, R.Y. and Lasisi, T.A., 2022. Survival Rate Analysis on Breast Cancer Cases at Univesity College Hospital, Ibadan, Nigeria. *Open Journal of Statistics*, 12, pp.238-260.
31. Knapp, G.C., Tansley, G., Olasehinde, O., Wuraola, F., Adisa, A., Arowolo, O., Olawole, M.O., Romanoff, A.M., Quan, M.L., Bouchard- Fortier, A. and Alatise, O.I., 2021. Geospatial access predicts cancer stage at presentation and outcomes for patients with breast cancer in southwest Nigeria: A population- based study. *Cancer*, 127(9), pp.1432-1438.

32. Olasehinde, O., Alatise, O., Omisore, A., Wuraola, F., Odujoko, O., Romanoff, A., Akinkuolie, A., Arowolo, O., Adisa, A., Knapp, G. and Famurewa, O., 2021. Contemporary management of breast cancer in Nigeria: Insights from an institutional database. *International journal of cancer*, 148(12), pp.2906-2914.
33. Olaogun, J.G., Omotayo, J.A., Ige, J.T., Omonisi, A.E., Akute, O.O. and Aduayi, O.S., 2020. Socio-demographic, pattern of presentation and management outcome of breast cancer in a semi-urban tertiary health institution. *Pan African Medical Journal*, 36(1).
34. Aliyu, U.M. and Kehinde, A., 2020. Tolerance and outcome of hypofractionated post-mastectomy radiotherapy among elderly breast cancer patients in a specialized center in Nigeria. *Translational Cancer Research*, 9(11), p.6833.
35. Awodutire, P.O., Kolawole, O.A. and Ilori, O.R., 2020. Data on the survival times of breast cancer patients in a Teaching Hospital, Osogbo. *Data in Brief*, 32.
36. Popoola, O.P., Oluwagbenga, A. and Popoola, A.T., 2019. Survival analysis of breast cancer in Nigeria. *Annals. Computer Science Series*, 17(1).
37. Ayandipo, O.O., Adeleye, A.O., Ulasi, I.B. and Ogundiran, T.O., 2019. Outcome of cerebral metastasectomy in select cases of brain metastases from breast cancer in Ibadan, Nigeria. *World Neurosurgery*, 127, pp.186-193.
38. Ntekim, A.I., Folasire, A.M. and Ali-Gombe, M., 2019. Survival pattern of rare histological types of breast cancer in a Nigerian institution. *Pan African Medical Journal*, 34(1).
39. Akinde, O.R., Phillips, A.A., Oguntunde, O.A. and Afolayan, O.M., 2015. Cancer mortality pattern in Lagos university teaching hospital, lagos, Nigeria. *Journal of cancer epidemiology*, 2015..

40. Makanjuola, S.B., Popoola, A.O. and Oludara, M.A., 2014. Radiation therapy: a major factor in the five-year survival analysis of women with breast cancer in Lagos, Nigeria. *Radiotherapy and Oncology*, 111(2), pp.321-326.
41. Kene, T.S., Odigie, V.I., Yusufu, L.M., Yusuf, B.O., Shehu, S.M. and Kase, J.T., 2010. Pattern of presentation and survival of breast cancer in a teaching hospital in north Western Nigeria. *Oman medical journal*, 25(2), p.104.
42. Woods, L.M., Rachet, B., O'Connell, D., Lawrence, G., Tracey, E., Willmore, A. and Coleman, M.P., 2009. Large differences in patterns of breast cancer survival between Australia and England: a comparative study using cancer registry data. *International journal of cancer*, 124(10), pp.2391-2399.
43. Fleming, K.A., Horton, S., Wilson, M.L., Atun, R., DeStigter, K., Flanigan, J., Sayed, S., Adam, P., Aguilar, B., Andronikou, S. and Boehme, C., 2021. The Lancet Commission on diagnostics: transforming access to diagnostics. *The Lancet*, 398(10315), pp.1997-2050.
44. Ingleby, F.C., Woods, L.M., Atherton, I.M., Baker, M., Elliss-Brookes, L. and Belot, A., 2022. An investigation of cancer survival inequalities associated with individual-level socio-economic status, area-level deprivation, and contextual effects, in a cancer patient cohort in England and Wales. *BMC Public Health*, 22, pp.1-12.
45. Niyonsenga, G., Gishoma, D., Segor, R., Uwayezu, M.G., Nikuze, B., Fitch, M. and Igiraneza, P.C., 2021. Knowledge, utilization and barriers of cervical cancer screening among women attending selected district hospitals in Kigali-Rwanda. *Canadian Oncology Nursing Journal*, 31(3), p.266.

46. Ssentongo, P., Lewcun, J.A., Candela, X., Ssentongo, A.E., Kwon, E.G., Ba, D.M., Oh, J.S., Amponsah-Manu, F., McDonald, A.C., Chinchilli, V.M. and Soybel, D.I., 2019. Regional, racial, gender, and tumor biology disparities in breast cancer survival rates in Africa: a systematic review and meta-analysis. *PloS one*, 14(11), p.e0225039.
47. Moodley, J., Constant, D., Mwaka, A.D., Scott, S.E. and Walter, F.M., 2021. Anticipated help seeking behaviour and barriers to seeking care for possible breast and cervical cancer symptoms in Uganda and South Africa. *ecancermedicalscience*, 15.
48. Zhu, J., Chen, J.G., Chen, Y.S., Zhang, Y.H., Ding, L.L. and Chen, T.Y., 2014. Female breast cancer survival in Qidong, China, 1972–2011: a population-based study. *BMC cancer*, 14(1), pp.1-7.
49. Yeole, B.B., Kumar, A.V.R., Kurkure, A. and Sunny, L., 2004. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. *Asian Pacific Journal of Cancer Prevention*, 5(3), pp.308-315.
50. Sankaranarayanan, R., Swaminathan, R., Brenner, H., Chen, K., Chia, K.S., Chen, J.G., Law, S.C., Ahn, Y.O., Xiang, Y.B., Yeole, B.B. and Shin, H.R., 2010. Cancer survival in Africa, Asia, and Central America: a population-based study. *The lancet oncology*, 11(2), pp.165-173.
51. Omar, S., Alieldin, N.H.M. and Khatib, O.M.N., 2007. Cancer magnitude, challenges and control in the Eastern Mediterranean Region. *EMHJ-Eastern Mediterranean Health Journal*, 13 (6), 1486-1496, 2007.
52. Khatib, O. and Aljurf, M., 2008. Cancer prevention and control in the Eastern Mediterranean region: the need for a public health approach. *Hematology/oncology and stem cell therapy*, 1(1), pp.44-52.

53. Allemani, C., Sant, M., Weir, H.K., Richardson, L.C., Baili, P., Storm, H., Siesling, S., Torrella- Ramos, A., Voogd, A.C., Aareleid, T. and Ardanaz, E., 2013. Breast cancer survival in the US and Europe: A CONCORD high- resolution study. *International journal of cancer*, 132(5), pp.1170-1181.
54. Kachuri, L., De, P., Ellison, L.F. and Semenciw, R., 2013. Cancer incidence, mortality and survival trends in Canada, 1970-2007. *Chronic diseases and injuries in canada*, 33(2).

UNDER PEER REVIEW